(0.16%) 5 222.68 points
(0.32%) 39 513 points
(-0.03%) 16 341 points
(-1.34%) $78.20
(-2.13%) $2.25
(1.14%) $2 366.90
(0.11%) $28.40
(1.48%) $1 005.50
(0.11%) $0.928
(-0.30%) $10.83
(-0.01%) $0.798
(-0.42%) $92.15
@ $42.06
Issued: 10 May 2024 @ 10:12
Return: 0.31%
Previous signal: May 9 - 10:47
Previous signal:
Return: -0.01 %
Live Chart Being Loaded With Signals
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases...
Stats | |
---|---|
Today's Volume | 464 942 |
Average Volume | 1.35M |
Market Cap | 7.67B |
EPS | $0 ( 2024-05-08 ) |
Next earnings date | ( $-0.610 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.80 |
ATR14 | $0.355 (0.84%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Coles N Anthony | Sell | 50 000 | Stock Option (Right to Buy) |
2024-04-01 | Coles N Anthony | Buy | 50 000 | Common Stock |
2024-04-01 | Coles N Anthony | Sell | 50 000 | Common Stock |
2024-03-04 | Coles N Anthony | Sell | 50 000 | Stock Option (Right to Buy) |
2024-03-04 | Coles N Anthony | Buy | 50 000 | Common Stock |
INSIDER POWER |
---|
83.42 |
Last 99 transactions |
Buy: 19 058 481 | Sell: 1 552 762 |
Volume Correlation
Cerevel Therapeutics Correlation
10 Most Positive Correlations | |
---|---|
RDUS | 0.932 |
PRDS | 0.903 |
JFU | 0.9 |
PHAT | 0.9 |
ABST | 0.89 |
APR | 0.881 |
ONTX | 0.879 |
FREQ | 0.87 |
ICON | 0.868 |
XENE | 0.866 |
10 Most Negative Correlations | |
---|---|
RMRM | -0.905 |
SBBP | -0.894 |
THMA | -0.882 |
GMII | -0.876 |
ALGM | -0.854 |
DTEA | -0.848 |
CFV | -0.843 |
VEDU | -0.832 |
PETV | -0.83 |
NRDS | -0.821 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cerevel Therapeutics Correlation - Currency/Commodity
Cerevel Therapeutics Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-5.63M (0.00 %) |
EPS: | $-2.67 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-5.63M (0.00 %) |
EPS: | $-2.67 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-4.90M (0.00 %) |
EPS: | $-2.32 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.650 |
Financial Reports:
No articles found.
Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators